Myasthenia Gravis

Myasthenia Gravis is an adult neuromuscular disorder that affects approximately 5 in 100,000 people.

It is due to a dysfunction of the immune system: the autoimmune reaction is directed against constituents of the neuromuscular junction, the interface between the nerve and the muscle, which results in a defect of transmission of the nerve impulse. This is manifested by fatigability and a lack of muscle strength.

 

Clinical trial ongoing at the Institute:

  • RA101495-02.301 : A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Confirm the Efficacy, Safety, and Tolerability of Zilucoplan in Subjects with Generalized Myasthenia Gravis

 

Acronym

RA101495-02.301

Study type RIPH1
Intervention Zilucoplan
Principal investigator Anthony Behin
Sponsor RAPharma
Fundings RAPharma
Study status In preparation
Recruitment status In preparation
Population Adult
  + infos on clinicaltrials.gov